Ningyan Q Zhang

US Patent:

20120195831, Aug 2, 2012

Filed:

Oct 7, 2010

Appl. No.:

13/500724

Inventors:

Ningyan Zhang - Houston TX, US
Hans Huber - Lansdale PA, US

International Classification:

A61K 39/395
C07K 16/46
G01N 33/574
C07K 17/02
A61P 35/00
A61K 51/10
A61K 49/16
A61K 49/22
A61K 49/04
C07K 16/28
C12N 9/96

US Classification:

424 149, 5303891, 5303873, 435 723, 4241741, 5303917, 435188, 5303913, 436501, 424 9341, 424 95, 424 93

Abstract:

The present invention relates to Her3 specific antibodies, preferably fully human or humanized antibodies and antigen-binding portions thereof. Nucleic acid molecules encoding the Her3 antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with aberrant expression of Her3 or Her2 including aberrant activation of each of these receptors.

US Patent:

20130115227, May 9, 2013

Filed:

Jul 13, 2011

Appl. No.:

13/809475

Inventors:

Renee C. Gaspar - Souderton PA, US
Paul J. Shughrue - West Chester PA, US
Fubao Wang - Dresher PA, US
Weirong Wang - Harleysville PA, US
Ningyan Zhang - Ambler PA, US
Wei-Qin Zhao - North Wales PA, US
Min Xu - Ambler PA, US
Alexander McCampbell - Chalfont PA, US

International Classification:

C07K 16/18

US Classification:

4241721, 5303891, 5303882, 435375, 435 71, 506 9, 435 792

Abstract:

Disclosed are antibodies that bind amyloid beta-derived diffusible ligands, also known as ADDLs. The antibodies are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.

US Patent:

20110286916, Nov 24, 2011

Filed:

Nov 16, 2009

Appl. No.:

13/130441

Inventors:

Ningyan Zhang - Ambler PA, US
Fubao Wang - Dresher PA, US
Andrew Bett - Lansdale PA, US
Anna Demartis - Rome, IT
Maurizio Nuzzo - Rome, IT
Paolo Monaci - Rome, IT
Stephen Blacklow - Cambridge MA, US
Jon Aster - Lexington MA, US

International Classification:

A61K 39/395
C12N 1/20
A61P 35/00
A61K 49/00
A61K 51/10
C12N 9/96
C07K 16/28
G01N 33/53

US Classification:

424 149, 5303891, 5303873, 4352521, 4352528, 4352525, 4352533, 435 792, 435 723, 424 91, 4241721, 4241781, 5303917, 5303913, 435188

Abstract:

The present invention relates to mammalian antibodies, preferably fully human monoclonal antibodies and antigen-binding portions thereof that specifically bind to a cell surface receptor, wherein the receptor protein is a Notch1 receptor protein. Some of the disclosed antibodies bind Notch1 to the exclusion of other members of the Notch receptor family, while other antibodies bind Notch 1 and Notch3. Nucleic acid molecules encoding the Notch antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of Notch1 or Notch3 including aberrant activation of each of these receptors.

US Patent:

20220267415, Aug 25, 2022

Filed:

Feb 15, 2022

Appl. No.:

17/671837

Inventors:

- Austin TX, US
- Mountain View CA, US
Paul HINTON - Sunnyvale CA, US
Ningyan ZHANG - Houston TX, US
Bruce KEYT - Hillsborough CA, US
Dean NG - San Francisco CA, US
Stephen CARROLL - Walnut Creek CA, US
Zhiqiang AN - Houston TX, US

Assignee:

The Board of Regents of The University of Texas System - Austin TX
IGM Biosciences, Inc. - Mountain View CA

International Classification:

C07K 16/10
A61P 31/14

Abstract:

This disclosure provides multimeric binding molecules that bind to SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing coronavirus disease 2019 (COVID-19).

US Patent:

20210371518, Dec 2, 2021

Filed:

Sep 12, 2019

Appl. No.:

17/275838

Inventors:

- Austin TX, US
- Palo Alto CA, US
Ningyan ZHANG - Houston TX, US
Xun GUI - Houston TX, US
Mi DENG - Dallas TX, US
Tao HUANG - Palo Alto CA, US
Qiang LIU - Palo Alto CA, US

International Classification:

C07K 16/28
A61P 35/02
A61K 45/06
A61K 39/395
A61K 47/68
A61K 51/10
G01N 33/574
A61K 47/69

Abstract:

The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

US Patent:

20210349096, Nov 11, 2021

Filed:

Jul 27, 2017

Appl. No.:

16/321745

Inventors:

- Austin TX, US
Zhiqiang AN - Houston TX, US
Ningyan ZHANG - Houston TX, US
Mi DENG - Plano TX, US
Jaehyup KIM - Houston TX, US
Xun GUI - Houston TX, US

International Classification:

G01N 33/574
G01N 33/50
G01N 15/14
G01N 21/64

Abstract:

Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

US Patent:

20210253680, Aug 19, 2021

Filed:

Jan 11, 2021

Appl. No.:

17/146187

Inventors:

- Austin TX, US
Zhiqiang An - Houston TX, US
Ningyan Zhang - Houston TX, US
Wei Xiong - Houston TX, US
Manuel A. Riquelme - San Antonio TX, US
Sumin Gu - San Antonio TX, US
Naomi Ledene Sayre - San Antonio TX, US

International Classification:

C07K 16/18
A61P 25/28
A61K 39/395
A61P 35/00
A61P 19/10

Abstract:

Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening arc provided.

US Patent:

20200079851, Mar 12, 2020

Filed:

Nov 8, 2019

Appl. No.:

16/678049

Inventors:

- Austin TX, US
Mi DENG - Plano TX, US
Wei XIONG - Pearland TX, US
Zhiqiang AN - Houston TX, US
Ningyan ZHANG - Houston TX, US
Xun GUI - Houston TX, US
Junke ZHENG - Shanghai, CN

International Classification:

C07K 16/28
G01N 33/574
C07K 16/30
A61K 45/06
A61K 39/395
A61P 35/02
C12N 15/113

Abstract:

The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.